Pharmaceutical Technology

OCTOBER 6, 2022

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. . Therapyx will develop and manufacture the IL-12-containing microspheres in the vaccine called GneX12.

Vaccine 147

Vaccine Vaccination Development Bacterium 147

pharmaphorum

JULY 27, 2022

The vaccine, codenamed BNT162b5, codes for “enhanced” prefusion spike proteins from the original wild-type strain of the virus and the Omicron variant that are designed to increase “the magnitude and breadth of the immune response.” Clinical data show strong neutralising antibody responses against Omicron BA.1,

Protein 122

Protein Immune Response Vaccine Vaccination 122

XTalks

NOVEMBER 5, 2024

per unit, included 958,903 units, each containing one ordinary share and three warrants to purchase additional shares at an exercise price of $4.38 is advancing novel nasal spray-based hydrogels with two innovative platforms: Capture and Contain (C&C) and Trap and Target (T&T). Polyrizon Ltd., million in gross proceeds.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccine 75

Vaccine Vaccination Immune Response Containment 75

Scienmag

NOVEMBER 3, 2020

The article by Dr. Ahmed Atia and colleagues is published in Current Pharmaceutical Biotechnology, 2020 Palm oil contains abundant quantities of vitamin E compounds, which include tocopherols and tocotrienols. These compounds have anti-oxidant effects, which protect cells from damage from toxic chemical produced by metabolic processes.

Immune Response 47

Immune Response Containment Research Allergies 47

Pharmaceutical Technology

FEBRUARY 15, 2023

The key component in all vaccines is one or more active ingredients made from viruses or bacteria, also called antigens, which generates an immune response. The active component of the Pfizer-BioNTech vaccine tozinameran, contains the genetic code for the coronavirus spike protein, inside a lipid (fat) capsule.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

The Pharma Data

JUNE 29, 2021

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. There is an excellent response to a second dose, even after a 10 month delay from the first.”.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

Scienmag

MAY 18, 2021

(Boston)–Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

Immune Response 41

Immune Response Reagent Research Protein 41

pharmaphorum

OCTOBER 5, 2022

Called NGoXIM, the vaccine is based on gonococcal OMVs combined with sustained-release microspheres containing recombinant human IL-12, supplied Intravacc’s US partner Therapyx, which are designed to boost the immune response to the antigens.

Vaccine 98

Vaccine Vaccination Immune Response Bacterium 98

Pharmaceutical Technology

NOVEMBER 22, 2022

According to CEPI: “Achieving the 100 Days Mission would give the world a fighting chance of containing a future outbreak before it spreads to become a global pandemic.”. Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

XTalks

NOVEMBER 6, 2020

Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccine Vaccination 75

Camargo

DECEMBER 13, 2021

An application submitted under 351(a), also known as a “stand-alone” application, must contain all safety and effectiveness information for a biological product and cannot depend on any other biological product. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

XTalks

AUGUST 26, 2020

The anti-inflammatory macrophages help in preventing an immune response from becoming dangerous, as seen with patients with autoimmune disease. This helps to ensure that inflammation naturally subsides after the initial immune response and promotes tissue repair.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

XTalks

APRIL 26, 2021

Moreover, a very strong immune response is needed to fend off the disease. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Malaria Vaccine Phase II Trial. At six months, 29.5

Vaccine 105

Vaccine Vaccination Immune Response Trials 105

The Pharma Data

JANUARY 31, 2021

Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Containment Research Development 52

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. There were no significant safety findings reported through day 29. Mixed Results.

Vaccine 98

Vaccine Vaccination Immune Response Antibody 98

pharmaphorum

SEPTEMBER 1, 2020

The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.

Vaccine 69

Vaccine Vaccination Trials Immune Response 69

pharmaphorum

AUGUST 16, 2020

Last month, interim results from a phase 1/2 trial of ChAdOx1 were published in The Lancet and showed the jab was tolerated and generated immune responses against the SARS-CoV-2 virus in all vaccinated participants.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

pharmaphorum

SEPTEMBER 25, 2020

DKN-01 is an antibody drug targeting the Dickkopf-1 (DKK1) protein, which is overexpressed in some forms of G/GEJ adenocarcinoma and is thought to be involved in tumour growth as well as dampening down the immune response against the cancer.

Immune Response 72

Immune Response Trials Drugs Containment 72

pharmaphorum

MAY 11, 2021

Unlike the strips of mRNA used to create Moderna’s COVID-19 vaccine, eRNA runs in a circle and has been specially modified to allow the body to read the code it contains.

RNA 98

RNA Drugs Protein Immune Response 98

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. THURSDAY, Dec. Researchers from the U.S.

Immune Response 52

Immune Response Containment Doctor Doctors 52

STAT News

NOVEMBER 3, 2022

The early-stage study, which is being sponsored by BioNTech, aims to evaluate safety, tolerability, and immunogenicity, or the ability to generate an immune response. The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.

Vaccine 97

Vaccine Vaccination Drug Delivery Systems Sales 97

XTalks

MAY 4, 2023

When a person with celiac disease eats something that contains gluten, their immune system attacks their small intestine, damaging the lining and interfering with the absorption of nutrients from food. Celiac disease is an autoimmune disorder that is triggered by the consumption of gluten, a protein found in barley, wheat and rye.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

XTalks

OCTOBER 24, 2024

In August 2024, Artax Biopharma completed patient recruitment for its Phase IIa trial of AX-158, exploring a new immune-modulating therapy for psoriasis. Nutrient-rich foods containing omega-3 fatty acids, prebiotics and curcumin could also help improve immune function and alleviate symptoms.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

The Pharma Data

DECEMBER 11, 2020

Thermo Fisher joined forces with the University of Oxford to harness its academic research capabilities in quantifying IgG antibodies and understanding each patient’s immune response to SARS-CoV-2. Sensitech technology helps to ensure the container refrigeration units can deliver a temperature control within +/- 0.25-degrees

Antibody 52

Antibody Vaccine Vaccination Containment 52

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccine Vaccination Genetic Engineering 98

XTalks

MAY 7, 2021

It was made using Novavax’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’s patented saponin-based Matrix-M as an adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Protein 97

Protein Vaccine Vaccination Trials 97

Pharmaceutical Technology

AUGUST 24, 2022

A central lab with a global footprint provides both the efficient transportation arrangement and scientific rigor required to unlock the valuable information contained within patients’ biological samples.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Worldwide Clinical Trials

JUNE 15, 2022

There have been a few cases lately where patients receiving gene therapy had a severe adverse effect because of their immune response to the mechanism of the AAV viral vector, based on their own genomic markers. Institutional Biosafety Committees (IBC) assess the risk of gene therapies to public health or the environment.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

XTalks

NOVEMBER 23, 2020

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccine 97

Vaccine Vaccination Clinical Trials Clinical Trials 97

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About Novavax.

Protein 52

Protein Vaccine Vaccination Immune Response 52

pharmaphorum

APRIL 26, 2022

As more research has been conducted, closer and unexpected links have been found between the microbiome of the gut, as one example, and other areas of the body, such as brain health and the immune system. The possibilities. Compelling advantages.

Containment 115

Containment Development Production Drugs 115

pharmaphorum

SEPTEMBER 14, 2021

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.

DNA 52

DNA Immune Response Genomics Genome 52

The Pharma Data

SEPTEMBER 14, 2020

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. Source link.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52

XTalks

JULY 21, 2022

Simply put, probiotic sodas are carbonated drinks that contain one or more probiotic ingredient(s). They can also help your body maintain a healthy community of microorganisms, produce substances that have desirable effects and influence your body’s immune response. But are probiotic sodas actually healthy? .

Containment 52

Containment Branding Bacteria Immune Response 52

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Immune Response 52

Immune Response In-Vivo Genetic Analysis Research 52